Cirius Therapeutics
Manufacturing · Michigan, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
161 E Michigan Ave Fl 4, Kalamazoo, Mich...Phone Number
(616) 344-4328Website
www.ciriustx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Cirius Therapeutics
Cirius Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for patients suffering from insulin resistance-related diseases, such as Type 2 Diabetes and Obesity. Their products include Azemiglitazone and GLP-1 receptor agonists, which aim to provide cardiometabolic benefits. The company is dedicated to addressing chronic metabolic diseases through advanced scientific research and clinical trials. Their intended clients are individuals affected by insulin resistance and related health conditions.Explore more
Cirius Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cirius Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Cirius Therapeutics is spiking on competitors!
Earning: See what the market has to say on Cirius Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Cirius Therapeutics has new funding data
Cirius Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Cirius Therapeutics
Product Launch: Get notified when Cirius Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Cirius Therapeutics had a recent Job posting/layoffs
Check if Cirius Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Cirius Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cirius Therapeutics
Compare insights from companies similar to Cirius Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cirius Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cirius Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cirius Therapeutics.
Cirius Therapeutics financials insights
Gather financial insights about Cirius Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$16.4M
2017
Series A
$40M
2025
Debt
$800K
Cirius Therapeutics Tech Stack
A closer look at the technologies used by Cirius Therapeutics
Cirius Therapeutics News & Media
Cirius Therapeutics Announces Presentation on CIR-0602K as Novel Diabetes Treatment at the American Diabetes Association's 2026 Scientific Sessions
GRAND RAPIDS, Mich., June 1, 2026 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, today announced that clinical data on the treatment of type 2 diabetes (T2D) with...Cirius Therapeutics Announces Gestational Diabetes Initiative
Supported by a Gates Foundation grant Addressing postpartum health burdens of gestational diabetes Gestational diabetes occurs in up to 20% of pregnancies Marked increases in subsequent chronic metabolic diseases for women who experience gestational diabetes GRAND RAPIDS, Mich., April 28,...Cirius Therapeutics to Highlight Cardiometabolic Benefits of CIR-0602K at Global Cardiovascular Clinical Trialists (CVCT) Forum 2025
Data from Phase 2 Trials Underscore Cardioprotective Potential GRAND RAPIDS, Mich., Dec. 9, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases driven by insulin resistance and metabolic dysfunction, announced today that...CIR-0602K Demonstrates Synergistic Metabolic Benefit with Tirzepatide: New Data Presented at ObesityWeek 2025
GRAND RAPIDS, Mich., Nov. 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by insulin resistance and metabolic dysfunction, will be presenting new data today at ObesityWeek® 2025 from preclinical obesity...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cirius Therapeutics
Sign Up For FreeTo access detailed company insights
Cirius Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for patients suffering from insulin resistance-related diseases, such as Type 2 Diabetes and Obesity. Their products include Azemiglitazone and GLP-1 receptor agonists, which aim to provide cardiometabolic benefits. The company is dedicated to... Read More
